Company profile: Sanofi
1.1 - Company Overview
Company description
- Provider of prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases, offering research, development, manufacturing, and marketing of innovative therapeutic solutions across diabetes care, human vaccines, innovative drugs, consumer healthcare (OTC for allergies, cough, cold, flu, digestive wellness), pain care, physical & mental wellness, patient engagement, emerging markets, animal health, and the new G enzyme.
Products and services
- Vaccines: Sanofi develops and distributes human vaccines that immunize against diverse infectious diseases, architected to protect populations and reduce disease burden through broad preventive coverage
- Diabetes Care: Sanofi delivers therapeutic products for diabetes management, engineered to improve patient outcomes through targeted treatments
- Consumer Healthcare: Sanofi offers over-the-counter self-care products, producing targeted treatments for allergies, cough, cold, flu, and digestive wellness
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sanofi
Endo
HQ: Ireland
Website
- Description: Provider of branded and generic pharmaceuticals for patient care, offering affordable, high-quality generics and treatments for unmet pelvic health needs; supplies products tailored to Canadian and emerging markets, and engages in public policy advocacy to enhance patient access, alongside a UK tax strategy focused on compliance and responsible planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endo company profile →
Pearl Therapeutics
HQ: United States
Website
- Description: Provider of unique dual and triple combination inhaled therapies for widely prevalent respiratory diseases, including chronic obstructive pulmonary disease, delivered via familiar metered dose inhalers to broaden patient access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pearl Therapeutics company profile →
Immunex
HQ: United States
Website
- Description: Provider of therapeutic products for cancer, infectious diseases, and autoimmune disorders. Develops, manufactures, and markets treatments including Enbrel for rheumatoid arthritis and Novantrone for acute nonlymphocytic leukemia and pain associated with prostate cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunex company profile →
Pieris Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology biotechnology programs, including 4-1BB bispecific programs developed with Pfizer, Servier, and Boston Pharmaceuticals, and potential future partnership royalties from sales of approved partnered immuno-oncology assets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pieris Pharmaceuticals company profile →
Ablynx
HQ: Belgium
Website
- Description: Provider of a proprietary Nanobody® technology platform for the discovery and development of therapeutic nanobodies—small single-domain antibody fragments—targeting serious human diseases including inflammation, haematology, oncology and pulmonary disease, with approximately 25 projects in the pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ablynx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sanofi
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sanofi
2.2 - Growth funds investing in similar companies to Sanofi
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sanofi
4.2 - Public trading comparable groups for Sanofi
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →